<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462486</url>
  </required_header>
  <id_info>
    <org_study_id>150998-006</org_study_id>
    <secondary_id>2014-004580-20</secondary_id>
    <secondary_id>SEQUOIA</secondary_id>
    <nct_id>NCT02462486</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of abicipar pegol in participants with neovascular&#xD;
      age-related macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2015</start_date>
  <completion_date type="Actual">June 6, 2019</completion_date>
  <primary_completion_date type="Actual">April 12, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Stable Vision at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Stable vision was defined as vision loss of fewer than 15 letters in Best-corrected Visual Acuity (BCVA) from baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. Study eye was defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) in the Study Eye at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Mixed-effect model for repeated measures (MMRM) analysis was used. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system that provides high-resolution imaging sections of the retina. SD-OCT is performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye. MMRM analysis was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With BCVA Gain of More Than 15 Letters From Baseline in the Study Eye at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA gain of more than 15 letters are noted. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision. Overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye: eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">949</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Abicipar Pegol 2 mg (2Q8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abicipar Pegol 2 mg (2Q12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab (rQ4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abicipar Pegol</intervention_name>
    <description>Abicipar pegol intravitreal injection.</description>
    <arm_group_label>Abicipar Pegol 2 mg (2Q12)</arm_group_label>
    <arm_group_label>Abicipar Pegol 2 mg (2Q8)</arm_group_label>
    <other_name>AGN-150998</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab intravitreal injection.</description>
    <arm_group_label>Ranibizumab (rQ4)</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Sham injection.</description>
    <arm_group_label>Abicipar Pegol 2 mg (2Q12)</arm_group_label>
    <arm_group_label>Abicipar Pegol 2 mg (2Q8)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of age-related macular degeneration in at least 1 eye&#xD;
&#xD;
          -  Best corrected visual acuity of 20/40 to 20/320 in the study eye&#xD;
&#xD;
          -  Best corrected visual acuity of 20/200 or better in the non-study eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of vitrectomy, macular surgery, or glaucoma surgery in the study eye&#xD;
&#xD;
          -  Cataract or refractive surgery in the study eye within the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Li</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Foundation Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnet Dulaney Perkins Eye Center - Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-4701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Centers, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Arkansas Retina Associates</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Win Retina</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of California</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Diagnostic Center</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialty Eye Care Medical Center, Inc.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Irvine Gavin Herbert Eye Institute</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697-4375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Orange County</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Retina Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Retina Consultants, Inc.</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Retina Associates</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Eye Specialist Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants, San Diego</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Southern California</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Riverside Medical Center</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center, Department of Ophthalmology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group, Inc.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Eye Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Associates</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Macula Specialists of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Lauderdale Eye Institute</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Florida Eye Institute</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associate of Florida, P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DuPage Medical Group</name>
      <address>
        <city>Downers Grove</city>
        <state>Illinois</state>
        <zip>60515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kovach Eye Institute</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Retina and Macula Associates</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wheaton Eye Clinic, Clinical Research Center, LLC</name>
      <address>
        <city>Wheaton</city>
        <state>Illinois</state>
        <zip>60187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sabates Eye Centers</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paducah Retinal Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Care Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants, P.C.</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates, Pc</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists of Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center of New Jersey, LLC</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Retina Associates</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maculacare - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Surgeons of Central NY, PC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associates, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose &amp; Throat Associates, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland, Inc</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242-5664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Retina, Inc.</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina &amp; Vitreous Center SO, PC</name>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <zip>97520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Retina Specialists, P.C.</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous of Texas</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Retina Specialists</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of South Texas, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strategic Clinical Research Group, LLC</name>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <zip>76087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, John Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wagner Macula and Retina Center</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Associates of Washington</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Eye Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Eye Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Save Sight Institute, University of Sydney Eye Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Retina Clinic and Day Surgery</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney West Retina</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Eye Research Australia</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist Eye Group</name>
      <address>
        <city>Glen Waverley</city>
        <state>Victoria</state>
        <zip>3150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Brasileiro de Cirurgia de Olhos - CBCO</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74210-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instistuto da Visao - Hospital de Olhos Ltda</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30330-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Oftalmologico de Sorocaba</name>
      <address>
        <city>Sorocaba</city>
        <state>Sao Paulo</state>
        <zip>18031-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Olhos Dr. Suel Abujamra</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01525-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Da Visao UNIFESP EPM (Universidade Federal de Sao Paulo - Escola Paulista de Medicina)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calgary Retina Consultants</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2H 0C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Health Care London - Ivey Eye Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Centre for Advanced Eye Therapeutics Inc</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Eye Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Retina Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3C0G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet-Glostrup</name>
      <address>
        <city>Glostrup</city>
        <state>Hovedstaden</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>C 5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>1068</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Imre Teaching Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budapest Retina Associates Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical Center</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ganglion Medical Centre</name>
      <address>
        <city>Pecs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszki Teaching Hospital</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Clinicizzato</name>
      <address>
        <city>Chieti</city>
        <state>Abruzzi</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Oculistica, Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Clinic - Fondazione IRCCS</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Oculistica- Dipartimento di Scienze Cliniche Universita di Milano</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <state>Piedmont</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi - SOD Oculistica, Dipartimento di Chirurgia e Medicina Traslazionale</name>
      <address>
        <city>Firenze</city>
        <state>Tuscany</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria Ospedaliera Pisana, Ospedale &quot;Nuovo S.Chiara&quot; Cisanello</name>
      <address>
        <city>Pisa</city>
        <state>Tuscany</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istuto di Recovero e Cura a Carattere Scientifico</name>
      <address>
        <city>Verona</city>
        <state>Vento</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Sant Orsola Malpighi Pad1, 4Piano, Studio Medici via Pelagio Palagi 9</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Oculistica DINOGMI Universita di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione G.B. Bietti-IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University Hospital</name>
      <address>
        <city>Nagakute</city>
        <state>Aichi</state>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Chukyo Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kameda Clinic</name>
      <address>
        <city>Kamogawa</city>
        <state>Chiba</state>
        <zip>296-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Sakura Medical Center</name>
      <address>
        <city>Sakura</city>
        <state>Chiba</state>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Urayasu Hospital</name>
      <address>
        <city>Urayasu</city>
        <state>Chiba</state>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogaki Tokushukai Hospital</name>
      <address>
        <city>Ogaki</city>
        <state>Gifu</state>
        <zip>503-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimura Eye And Internal Medicine Hospital</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0029</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Prefectural Amagasaki Hospital General Medical Center</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Ibaraki Medical Center</name>
      <address>
        <city>Inashiki</city>
        <state>Ibaraki</state>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mito Kyodo General Hospital</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <zip>310-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otakeganka Tsukimino Clinic</name>
      <address>
        <city>Yamato</city>
        <state>Kanagawa</state>
        <zip>242-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kikuna Yuda Eye Clinic</name>
      <address>
        <city>Kanagawa</city>
        <state>Kanto</state>
        <zip>222-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iida Municipal Hospital</name>
      <address>
        <city>Iida</city>
        <state>Nagano</state>
        <zip>395-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seirei Hamamatsu General Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>430-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Hospital</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chofu Eye Clinic</name>
      <address>
        <city>Chofu</city>
        <state>Tokyo</state>
        <zip>182-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hachioji Medical Center</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>193-0998</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takeuchi Eye Clinic</name>
      <address>
        <city>Taito</city>
        <state>Tokyo</state>
        <zip>111-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Kinen Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ideta Eye Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Japanese Red Cross Nagasaki Genbaku Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-0851</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Nara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Jinshikai Nishi Eye Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>537-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musashi Dream Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>543-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tane Memorial Eye Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>550-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Hospital</name>
      <address>
        <city>Tilburg</city>
        <state>North Brabant</state>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oogziekenhuis Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <state>North Holland</state>
        <zip>3011 BH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macula D&amp;T Eye Center</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimum Profesorskie Centrum Okulistyki</name>
      <address>
        <city>Gdansk</city>
        <zip>80-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Okulistyczna Jasne Blonia</name>
      <address>
        <city>Lodz</city>
        <zip>91-134</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyki i Mikrochirurgii</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-424</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Eye Hospital</name>
      <address>
        <city>Warsaw</city>
        <zip>01-364</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Ocular Diseases of RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Fyodorov Eye Microsurgery Federal State Institution</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasteur Medical Centre</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Actons Privat Practice</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pretoria Eye Institute, Private Practice</name>
      <address>
        <city>Pretoria</city>
        <zip>0007</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation, Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Uni Med Fac</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Uni Med Fac</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <state>Camberley</state>
        <zip>GU17 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <state>Derbyshire</state>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ESNEFT Essex County Hospital</name>
      <address>
        <city>Colchester</city>
        <state>Essex</state>
        <zip>CO4 5JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Eye Hospital, John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Headington</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>North West England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey Hospital</name>
      <address>
        <city>Guildford</city>
        <state>South East</state>
        <zip>S10 2TB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust, Good Hope Hospital</name>
      <address>
        <city>Sutton Coldfield</city>
        <state>Staffordshire</state>
        <zip>B75 7RR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF4 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary (BRI)</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD18 4JN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals</name>
      <address>
        <city>Sheffield</city>
        <state>Yorkshire</state>
        <zip>S10 2TB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnet Hospital</name>
      <address>
        <city>Barnet</city>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Eye Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnet Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>EN53DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of St. Cross</name>
      <address>
        <city>Rugby</city>
        <zip>CV22 5PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospitals Sunderland NHS</name>
      <address>
        <city>Sunderland</city>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>July 17, 2020</results_first_submitted>
  <results_first_submitted_qc>July 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2020</results_first_posted>
  <disposition_first_submitted>March 25, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 29, 2019</disposition_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02462486/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02462486/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abicipar Pegol 2 mg (2Q8)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="P2">
          <title>Abicipar Pegol 2 mg (2Q12)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab (rQ4)</title>
          <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="316"/>
                <participants group_id="P2" count="315"/>
                <participants group_id="P3" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="223"/>
                <participants group_id="P3" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure:Missed Exclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Abicipar Pegol 2 mg (2Q8)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="B2">
          <title>Abicipar Pegol 2 mg (2Q12)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="B3">
          <title>Ranibizumab (rQ4)</title>
          <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="316"/>
            <count group_id="B2" value="315"/>
            <count group_id="B3" value="318"/>
            <count group_id="B4" value="949"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="316"/>
                    <count group_id="B2" value="315"/>
                    <count group_id="B3" value="318"/>
                    <count group_id="B4" value="949"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.9" spread="8.6"/>
                    <measurement group_id="B2" value="76.2" spread="8.3"/>
                    <measurement group_id="B3" value="75.9" spread="8.4"/>
                    <measurement group_id="B4" value="76.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="316"/>
                    <count group_id="B2" value="315"/>
                    <count group_id="B3" value="318"/>
                    <count group_id="B4" value="949"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="538"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="316"/>
                    <count group_id="B2" value="315"/>
                    <count group_id="B3" value="318"/>
                    <count group_id="B4" value="949"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="264"/>
                    <measurement group_id="B4" value="796"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best Corrected Visual Acuity (BCVA) for Per Protocol Population</title>
          <description>BCVA was measured using an eye chart and is reported as number of letters read correctly using Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (0 to 100 letters) in study eye. Lower number of letters read correctly, worse the vision. Study eye: eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (Day 1) was selected. If values for both eyes were identical, participant selected non-dominant eye, or else right eye was selected.</description>
          <population>Per Protocol (PP) population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="265"/>
                    <count group_id="B3" value="299"/>
                    <count group_id="B4" value="831"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="12.1"/>
                    <measurement group_id="B2" value="56.3" spread="12.5"/>
                    <measurement group_id="B3" value="57.0" spread="12.3"/>
                    <measurement group_id="B4" value="57.0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BCVA for ITT Population</title>
          <description>BCVA was measured using an eye chart and is reported as number of letters read correctly using Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (0 to 100 letters) in study eye. Lower number of letters read correctly, worse the vision. Study eye: eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (Day 1) was selected. If values for both eyes were identical, participant selected non-dominant eye, or else right eye was selected.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="316"/>
                    <count group_id="B2" value="315"/>
                    <count group_id="B3" value="318"/>
                    <count group_id="B4" value="949"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="12.3"/>
                    <measurement group_id="B2" value="56.4" spread="12.5"/>
                    <measurement group_id="B3" value="57.1" spread="12.3"/>
                    <measurement group_id="B4" value="56.9" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Retinal Thickness (CRT)</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system that provides high-resolution imaging sections of retina. SD-OCT was performed in study eye after pupil dilation.Study eye was defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
          <population>Number analyzed is the number of participants with data available at the Baseline.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="316"/>
                    <count group_id="B2" value="314"/>
                    <count group_id="B3" value="318"/>
                    <count group_id="B4" value="948"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="380.3" spread="117.9"/>
                    <measurement group_id="B2" value="378.2" spread="123.8"/>
                    <measurement group_id="B3" value="382.4" spread="130.3"/>
                    <measurement group_id="B4" value="380.3" spread="124.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)</title>
          <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision related function. The overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding the general health score. Overall composite score was calculated based on mean of non-missing subscales.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="316"/>
                    <count group_id="B2" value="315"/>
                    <count group_id="B3" value="318"/>
                    <count group_id="B4" value="949"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.4" lower_limit="33" upper_limit="98"/>
                    <measurement group_id="B2" value="78.3" lower_limit="20" upper_limit="99"/>
                    <measurement group_id="B3" value="77.3" lower_limit="27" upper_limit="100"/>
                    <measurement group_id="B4" value="78" lower_limit="20" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Stable Vision at Week 52</title>
        <description>Stable vision was defined as vision loss of fewer than 15 letters in Best-corrected Visual Acuity (BCVA) from baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. Study eye was defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Per Protocol (PP) population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (rQ4)</title>
            <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stable Vision at Week 52</title>
          <description>Stable vision was defined as vision loss of fewer than 15 letters in Best-corrected Visual Acuity (BCVA) from baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. Study eye was defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
          <population>Per Protocol (PP) population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8"/>
                    <measurement group_id="O2" value="91.3"/>
                    <measurement group_id="O3" value="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, if the lower limit of the 95.1% confidence interval for the difference between an abicipar group and ranibizumab is greater than or equal to -10%, non-inferiority of abicipar group is established.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as stratification factor.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, if the lower limit of the 95.1% confidence interval for the difference between an abicipar group and ranibizumab is greater than or equal to -10%, non-inferiority of abicipar group is established.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as stratification factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) in the Study Eye at Week 52</title>
        <description>BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Mixed-effect model for repeated measures (MMRM) analysis was used. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>PP population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (rQ4)</title>
            <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) in the Study Eye at Week 52</title>
          <description>BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Mixed-effect model for repeated measures (MMRM) analysis was used. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
          <population>PP population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="14.3"/>
                    <measurement group_id="O2" value="7.3" spread="13.8"/>
                    <measurement group_id="O3" value="8.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, non-inferiority of abicipar is established if the lower limit of the CI is &gt; - 5.0 letters.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>MMRM included treatment, region, BL BCVA, BL CRT ≤400 or &gt;400, choroidal neovascularization lesion type, visit, visit-by-BL BCVA interaction, and treatment-by-visit interaction term as covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, non-inferiority of abicipar is established if the lower limit of the CI is &gt; - 5.0 letters.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>MMRM included treatment, region, BL BCVA, BL CRT ≤400 or &gt;400, choroidal neovascularization lesion type, visit, visit-by-BL BCVA interaction, and treatment-by-visit interaction term as covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52</title>
        <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system that provides high-resolution imaging sections of the retina. SD-OCT is performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye. MMRM analysis was used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Intent-to-treat (ITT) Population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (rQ4)</title>
            <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system that provides high-resolution imaging sections of the retina. SD-OCT is performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye. MMRM analysis was used.</description>
          <population>Intent-to-treat (ITT) Population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-146.8" spread="118.1"/>
                    <measurement group_id="O2" value="-141.7" spread="127.1"/>
                    <measurement group_id="O3" value="-147.1" spread="126.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
            <estimate_desc>MMRM included treatment, region, BL BCVA, BL CRT, choroidal neovascularization lesion type, visit, visit-by-baseline CRT interaction, and treatment-by-visit interaction term as covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.4</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>16.5</ci_upper_limit>
            <estimate_desc>MMRM included treatment, region, BL BCVA, BL CRT, choroidal neovascularization lesion type, visit, visit-by-baseline CRT interaction, and treatment-by-visit interaction term as covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With BCVA Gain of More Than 15 Letters From Baseline in the Study Eye at Week 52</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA gain of more than 15 letters are noted. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>ITT Population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (rQ4)</title>
            <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With BCVA Gain of More Than 15 Letters From Baseline in the Study Eye at Week 52</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA gain of more than 15 letters are noted. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-dominant eye, or else right eye was selected as study eye.</description>
          <population>ITT Population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as the stratification factor.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as the stratification factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Week 52</title>
        <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision. Overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye: eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>ITT population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (rQ4)</title>
            <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Week 52</title>
          <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision. Overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye: eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.</description>
          <population>ITT population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.7"/>
                    <measurement group_id="O2" value="2.4" spread="0.7"/>
                    <measurement group_id="O3" value="4.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>MMRM included treatment group, region, baseline BCVA in the study eye, baseline VFQ score, visit, and treatment by visit interaction as fixed covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>MMRM included treatment group, region, baseline BCVA in the study eye, baseline VFQ score, visit, and treatment by visit interaction as fixed covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose up to last dose (Up to Week 104)</time_frame>
      <desc>Safety population included all treated participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abicipar Pegol 2 mg (2Q8)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="E2">
          <title>Abicipar Pegol 2 mg (2Q12)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab (rQ4)</title>
          <description>Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Myocardial oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retinal fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retinal pigment epithelial tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retinal vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vitritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Autoimmune uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Anterior chamber inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Serous retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pharyngo-oesophageal diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Arteritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Infective aortitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Monoclonal immunoglobulin present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Urine electrolytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bone loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Retroperitoneal neoplasm metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of head and neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Piriformis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vertebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="166" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Registry Team</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>1-800-347-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

